A carregar...
Idelalisib in the management of lymphoma
Inhibition of the phosphatidylinositol-3-kinase (PI3K) pathway as an anticancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5161010/ https://ncbi.nlm.nih.gov/pubmed/27252232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-02-702761 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|